Latest broker research reports from Marwadi Financial Services buy, sell, hold, neutral recommendations along with
share price targets forecast and upside.
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
Considering the FY23 EPS of Rs 7.66 on a post issue basis, the company is going to list at a P/E of 39.16x with a market cap of Rs.25,755mn whereas its peers Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, Narayana Hrudalaya Limited, Max Healthcare Institute Limited, Krishna Institute of Medical Sciences Limited, Healthcare Global Enterprises Limited, Global Health Limited are trading at a P/E of 92.0x, 48.2x, 35.2x, 53.5x, 46.9x, 253.0x, 59.1x.
The IPO is priced conservatively at a 22% discount to the Net Asset Value (NAV) of the units. Post-IPO, the equity value of the trust will be Rs. 1,51,500 mn. and NAV per unit in relation to the offer price shall be 0.78 at the upper price band.
Considering the TTM (Dec-22) /FY23 Annualized EPS of Rs 29.61/33.16 on a post-issue basis, the company is going to list at a P/E of 36.47/32.57x with a market cap of Rs. 4,32,636 mn. whereas its peers namely Sun Pharmaceuticals, Cipla, Alkem Lab and Torrent Pharmaceutical are trading at a P/E of 29.43x, 27.45x, 39.24x, 43.65x.
